HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on CASI Pharmaceuticals and maintained a $10 price target.
August 14, 2023 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CASI Pharmaceuticals has received a reiterated 'Buy' rating and a maintained price target of $10 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for CASI Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100